ONXEO - BUY | EUR1.26 Establishing US presence with new CEO and additional EUR 12M financing New CEO to drive clinical development and establish US presence With a total of EUR 29.9M cash on hand, cash runway toward 2Q 2023 Progressing with clinical and preclinical pipeline
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
ONXEO - BUY | EUR1.22(+85%) Encouraging signs of efficacy for AsiDNA in combination with chemotherapy in NSCLC DRIIV-1b delivers encouraging new data Greater responses than with previous treatments A phase II randomized trial in preparation for H2-2021 A partnership agreement is possible in H2 2021
DNA Damage Response is a very interesting approach to treating cancer, which has become reality with the introduction of a first class of drugs known as PARP inhibitors. Not only have they created a market which is already worth USD2bn and still growing rapidly with the addition of new indications, but they have also been the subject of fierce M&A battles between large pharma companies. Pfizer outbid Sanofi to buy Medivation, GSK bought Tesaro and AZ shared Lynparza with Merck. In each case, bil...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.